NCT05007145 (REVO) is a Phase 2 clinical trial of PD-1 inhibitor in Esophageal Neoplasms, sponsored by Fujian Cancer Hospital.

Who is sponsoring NCT05007145?

NCT05007145 is sponsored by Fujian Cancer Hospital.

What drugs are being tested in NCT05007145?

Interventions in NCT05007145: PD-1 inhibitor, Albumin-Bound Paclitaxel, Cisplatin, Radiation.

What condition does NCT05007145 study?

NCT05007145 studies Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma.

Is NCT05007145 still recruiting?

NCT05007145 is currently status unknown. Last updated 21 December 2021.

Last reviewed 2021-12-21 · How we verify

NCT05007145: REVO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Status unknown Phase 2 Last updated 21 December 2021

What this trial tests

Phase 2 trial testing PD-1 inhibitor in Esophageal Neoplasms in 92 participants. Status unknown.

Timeline

15 August 2021

Primary endpoint
31 August 2023

31 August 2023

Quick facts

Lead sponsor	Fujian Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	92
Start date	15 August 2021
Primary completion	31 August 2023
Estimated completion	31 August 2023
Sites	6 locations across China

Drugs / interventions tested

PD-1 inhibitor — full drug profile →
Albumin-Bound Paclitaxel — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Radiation

Conditions studied

Esophageal Neoplasms — all drugs for Esophageal Neoplasms →
Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →

Sponsor

Fujian Cancer Hospital

Who can join

Adults 18 to 75, any sex, with Esophageal Neoplasms or Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore the efficacy and safety of compare the efficacy and safety of PD-1 inhibitor and chemotherapy（treatment group） with chemoradiotherapy（control group） in neoadjuvant treatment of resectable thoracic esophageal squamous cell carcinoma.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma.
An L, Li M, Jia Q. · · 2023 · cited 129× · PMID 37598158 · DOI 10.1186/s12943-023-01839-2
Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions.
Jiang M, Hu Y, Lin G, Chen C, et al · · 2023 · cited 18× · PMID 37325652 · DOI 10.3389/fimmu.2023.1177085
Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review.
Noori M, Jafari-Raddani F, Davoodi-Moghaddam Z, Delshad M, et al · · 2024 · cited 17× · PMID 38183112 · DOI 10.1186/s12935-023-03183-3
Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future.
Liu Y. · · 2023 · cited 16× · PMID 37753366 · DOI 10.3748/wjg.v29.i34.5020
From tumor microenvironment to emerging biomarkers: the reshaping of the esophageal squamous cell carcinoma tumor microenvironment by neoadjuvant chemotherapy combined with immunotherapy.
Qiu Z, Li Z, Liu X, Zhang R, et al · · 2024 · cited 6× · PMID 39703499 · DOI 10.3389/fimmu.2024.1478922
Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer.
Ahmad MU, Javadi C, Poultsides GA. · · 2022 · cited 6× · PMID 35406527 · DOI 10.3390/cancers14071755
Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO).
Wang P, Chen Y, Wang F, Chen M, et al · · 2025 · cited 1× · PMID 41184224 · DOI 10.1038/s41467-025-64660-z

Verify or expand the search:

Other trials of PD-1 inhibitor

Trials testing the same drug.

NCT07182565 — Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcin · Phase 1, PHASE2 · recruiting
NCT07007182 — Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer · Phase 2 · not yet recruiting
NCT07072351 — Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Ade · Phase 1, PHASE2 · recruiting
NCT07142200 — A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy a · Phase 2 · not yet recruiting
NCT06841679 — Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients Wi · Phase 2, PHASE3 · recruiting

Other recruiting trials for Esophageal Neoplasms

Currently open trials in the same condition.

NCT07482566 — Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer · NA · recruiting
NCT07272382 — Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer · NA · recruiting
NCT06469944 — Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First · Phase 1, PHASE2 · recruiting
NCT07035587 — Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity · recruiting
NCT06445972 — Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) · Phase 1, PHASE2 · recruiting

Other Fujian Cancer Hospital trials

Trials by the same sponsor.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05007145 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
Last refreshed: 21 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05007145.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing